Sangamo showcases Fabry progress at WORLDSymposium™

Uncategorized

Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing

BRISBANE, Calif. & BOSTON --(BUSINESS WIRE)--Jul. 20, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered